Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Galapagos NV (GLPG)

56.69   0.89 (1.59%) 07-02 19:00
Open: 55.02 Pre. Close: 55.8
High: 56.7 Low: 55.01
Volume: 181,113 Market Cap: 3,726(M)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 56.75 - 56.97 56.97 - 57.22
Low: 54.42 - 54.65 54.65 - 54.92
Close: 56.25 - 56.63 56.63 - 57.07

Technical analysis

as of: 2022-07-01 4:22:20 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 68.52     One year: 80.03
Support: Support1: 54.5    Support2: 51.93
Resistance: Resistance1: 58.66    Resistance2: 68.52
Pivot: 54.67
Moving Average: MA(5): 55.97     MA(20): 55.22
MA(100): 60.61     MA(250): 57.66
MACD: MACD(12,26): -0.3     Signal(9): -0.7
Stochastic oscillator: %K(14,3): 75.5     %D(3): 66.1
RSI: RSI(14): 53.7
52-week: High: 72.11  Low: 46.4
Average Vol(K): 3-Month: 292 (K)  10-Days: 256 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GLPG ] has closed below upper band by 10.9%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 01 Jul 2022
Ectonucleotide Pyrophosphatase Market Giants Spending Is Going To Boom |Eli Lilly and Co, Galapagos NV, Ono Pharmaceutical Co Ltd, Ribomic Inc, TaiwanJ Pharmaceuticals Co Ltd – Indian Defence News - Indian Defence News

Fri, 01 Jul 2022
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Biggest Innovation with Top Key Players -Allergan Plc, Galapagos NV, Merck & Co Inc, Syntiron LLC, Valevia UK Ltd – Indian Defence News - Indian Defence News

Wed, 29 Jun 2022
Are Medical Stocks Lagging Galapagos (GLPG) This Year? - Nasdaq

Tue, 21 Jun 2022
Galapagos enters cell therapy space with acquisition of CellPoint, AboundBio (NASDAQ:GLPG) - Seeking Alpha

Mon, 20 Jun 2022
Galapagos increases share capital through subscription right exercises - Yahoo Finance UK

Wed, 15 Jun 2022
Do Analysts Agree Wednesday on Galapagos ADR Representing Ord Shs (GLPG) Stock's Target Price? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 66 (M)
Shares Float 40 (M)
% Held by Insiders 0 (%)
% Held by Institutions 19.7 (%)
Shares Short 549 (K)
Shares Short P.Month 686 (K)

Stock Financials

EPS -2.05
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 40.31
Profit Margin (%) -24.9
Operating Margin (%) -25
Return on Assets (ttm) -1.5
Return on Equity (ttm) -4.8
Qtrly Rev. Growth 19.7
Gross Profit (p.s.) -0.13
Sales Per Share 7.72
EBITDA (p.s.) -1.8
Qtrly Earnings Growth 0
Operating Cash Flow -445 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -27.66
PEG Ratio -29.5
Price to Book value 1.4
Price to Sales 7.33
Price to Cash Flow -8.38

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.